Ron Bentsur Acquires 4,500 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur bought 4,500 shares of the firm’s stock in a transaction that occurred on Tuesday, December 24th. The shares were acquired at an average cost of $4.65 per share, for a total transaction of $20,925.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,270,924 shares in the company, valued at $15,209,796.60. The trade was a 0.14 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ron Bentsur also recently made the following trade(s):

• On Friday, November 15th, Ron Bentsur acquired 20,000 shares of Nuvectis Pharma stock. The shares were bought at an average cost of $4.92 per share, with a total value of $98,400.00.

Nuvectis Pharma Price Performance

Shares of NVCT opened at $5.22 on Friday. The firm has a market capitalization of $100.86 million, a PE ratio of -4.50 and a beta of 0.20. The company’s 50-day moving average is $6.26 and its 200-day moving average is $6.46. Nuvectis Pharma, Inc. has a fifty-two week low of $4.44 and a fifty-two week high of $12.10.

Nuvectis Pharma (NASDAQ:NVCT) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.01. During the same quarter last year, the company earned ($0.37) EPS. Analysts predict that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.

Institutional Trading of Nuvectis Pharma

Institutional investors have recently added to or reduced their stakes in the company. Iridian Asset Management LLC CT acquired a new stake in shares of Nuvectis Pharma during the third quarter worth $348,000. Geode Capital Management LLC boosted its holdings in Nuvectis Pharma by 49.8% in the 3rd quarter. Geode Capital Management LLC now owns 79,716 shares of the company’s stock valued at $501,000 after purchasing an additional 26,489 shares during the period. Renaissance Technologies LLC grew its position in shares of Nuvectis Pharma by 20.7% during the 2nd quarter. Renaissance Technologies LLC now owns 74,500 shares of the company’s stock worth $472,000 after purchasing an additional 12,800 shares in the last quarter. Nations Financial Group Inc. IA ADV bought a new position in shares of Nuvectis Pharma during the third quarter worth approximately $63,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Nuvectis Pharma in the second quarter valued at approximately $58,000. 96.77% of the stock is currently owned by institutional investors.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.